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Preclinical evaluation of novel imidazoacridinone derivatives with potent
activity against experimental colorectal cancer
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Summary Novel imidazoacridinone derivatives, C1310 and C1311, have been evaluated for their potential to
inhibit tumour cell growth in vitro and in vivo. A cell line panel, including seven human and murine colon
carcinoma cell lines and three in vivo models, was used. The compounds were found to be potent inhibitors of
tumour cell growth with IC50 values ranging between 10 nm and 2 gLM in human colon cancer cell lines.
Statistically significant tumour growth delay (P<0.01) was observed after a single intraperitoneal (i.p.) dose of
C1311 (100 mg kg-l body weight) in MACISA, MAC29 murine and HT29 human adenocarcinomas of the
colon. Rapid accumulation of fluorescence of both C1310 and C1311 was seen in the nuclei of HT29 human
colon tumour cells in culture. C1311 was also found to bind into calf thymus DNA as shown by
spectrophotometric titration and thermal denaturation and to cause early inhibition of thymidine incorporation
in HT29 cells in vitro. The results of this study suggest that C1311 should be considered as a candidate for
clinical development.
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Many of the most potent currently available agents for
cancer chemotherapy interact directly in one way or another
with DNA. Among those causing DNA damage are cross-
linking and alkylating agents like cisplatinum and cyclopho-
sphamide (Roberts and Pascoe, 1972; Ramonas et al., 1981),
which form covalent bonds with DNA, drugs which form
complexes or intercalate by hydrophobic interaction and/or
hydrogen bond formation like actinomycin D (Farber et al.,
1960), or drugs acting as anti-metabolites competing with
native bases like 5-fluorouracil (5-Fu) or fludarabine (Cheson,
1992). Intercalation is reported to be a common feature of
anthracyclines and acridine derivatives, including agents such
as doxorubicin, dauno-rubicin, mitoxantrone and nitracrine
(DiMarco, 1975; Denny, 1989; Konopa, 1990), which have
proven to be clinically highly active against a variety of
tumours and have been shown to cause cell death by
subsequent inhibition of DNA synthesis (Piestrzeniewcz et
al., 1987; Mazerska et al., 1990; Burr-Furlong et al., 1978).
The ability to intercalate is a useful property of some drugs
(Hernandez et al., 1995); however, DNA binding by
intercalation alone may not be sufficient for anti-tumour
activity. It is widely thought that the most active anti-tumour
DNA intercalators work by stabilising the cleavable DNA-
protein complex formed by the enzyme topoisomerase II,
resulting in lethal strand breaks (Drlica and Franco, 1988).
The most widely used intercalating agent so far,
doxorubicin, is known to induce cardiotoxicity by free
radical formation from the doxorubicin redox cycle (Work-
man and Graham, 1993), which causes severe side-effects in
doxorubicin chemotherapy (Weiss et al., 1986). Therefore, a
series of imidazoacridinones has recently been developed in
an effort to generate antineoplastic agents, which combine
common characteristics of acridines and anthracyclines
essential for anti-cancer activity, such as planar structure
and polycyclic nucleus, with higher affinity to target DNA
and resistance to production of radicals by enzymatic
reduction (Cholody et al., 1990a). Diethylamino groups
thought to be capable of binding electrostatically to
phosphate moieties of DNA were introduced (Cholody et
al., 1990b), and a pyrazole ring was added to increase the
electron density of the 7t ring system preventing free radical
generation (Cholody et al., 1990a). Preliminary screening
results for several of these compounds showed cytotoxic
activity towards HeLaS3 cells and anti-tumour activity
against P388 leukaemia (Cholody et al., 1990a,b), B16
melanoma and colon adenocarcinoma C26 and C38
(Kusnierczyk et al., 1994) in mice.
In this article, we report the preclinical evaluation of two
novel acridine derivatives, imidazoacridinones C1310 and
C1311 (Figure 1). Studies by LH Patterson (personal
communication) have shown that these compounds do not
form free oxygen radicals. This study was designed to
examine the in vitro and in vivo activity of these clinical
candidate compounds against colon tumours and to
investigate further the biological and biochemical properties
in order to provide information that might aid the decision-
making process.
Materials and methods
Drugs
C1310, 5-[[diethylamino)ethyl]amino]-8-hydroxy-1-methylimi-
dazo-[4,5,1 -de] -acridine -6 - one hydrochloride and C1311, 5-
[[diethylamino)ethyl]amino] - 8 - hydroxyimidazo [4,5,1 - de]
acridine-6-one dihydrochloride (Figure 1), were synthesised at
the Technical University of Gdansk (Gdansk, Poland).
Doxorubicin and 5-fluorouracil and any other chemicals or
reagents used in these studies were purchased from Sigma-
Aldrich Ltd. (Poole, Dorset, UK). Drug stocks were prepared
in normal saline solution.
Cell culture and cell growth assays
Culture medium and supplements were purchased from Life
Technologies (Paisley, UK), Northumbria Biologicals
(Cramlington, UK) and Costar Limited (High Wycombe,
UK). All human tumour cell lines were obtained from the
repository of the National Cancer Institute in vitro cancer
screen (Frederick, MD, USA). The MAC tumour cell lines
were derived and established from murine adenocarcinoma of
the colon as described previously (Phillips et al., 1990;
Double et al., 1975). The mouse leukaemia cell line, WEHI-
3B, was purchased from the European Collection of Animal
Cell Cultures (Salisbury, UK). WEHI-3B and the human
chronic myelogenous leukaemia cell line, K-562, grew in
suspension; all other cell lines were monolayer cultures.
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In vitro cytotoxicity
To assess the effects of C1310/1311 on tumour cell growth,
exponentially growing cells (2 x 103 per well) were plated on
96-well plates in 100 ,l complete medium (RPMI-1640
supplemented with 2 mM L-glutamine and 10% fetal bovine
serum). After 24 h, 100 ,l of drug solutions (prepared as
twice the final concentration in complete medium) was added
in increasing concentrations to a final volume of 200,l per
well. Growth of drug-treated cells was compared with
untreated control cells and quantified after 6 days by 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide
(MTT) reduction as described elsewhere (Mosmann, 1983;
Alley et al., 1988). The formazan product of MTT reduction
was dissolved in 150 ,l dimethyl sulphoxide (DMSO) (Fisons
Scientific Equipment, Loughborough, UK) and absorbance at
550 nm was measured with a Labsystems Multiskan PLUS
plate reader (Labsystems Group Ltd., Basingstoke, UK). IC50
and total growth inhibition (TGI) drug concentrations were
calculated as reported before (Monks et al., 1991) and
represent the mean of three independent experiments.
Influence of duration of exposure
The effect of the length of the exposure period was tested in
the human colon carcinoma cell line, HT29, and the murine
line, MAC15A, by seeding 1 x 106 exponentially growing cells
into 25 cm2 tissue culture flasks. After 24 h, drug was added
at IC50 and TGI concentrations of C 310/Cl 311 as
determined by 6 day MTT assay for 1, 4, 8, 24 and 144 h.
At each time point, cells were washed twice with Hanks'
balanced salts solution (HBSS), counted using trypan blue
and 5000 viable cells per well were replated in 96-well plates
followed by an additional incubation for 6 days in drug-free
medium. Cell proliferation was assayed by MTT reduction as
described above.
In vivo anti-tumour activity
Animals and tumour systems Pure-strain NMRI mice aged
8 10 weeks from an inbred colony were used for the MAC
transplantable murine colon carcinoma studies and NCR
nude mice obtained from the NCI were used in the human
xenograft model. The mice received CRM diet (Labsure,
Croydon, UK) and water ad libitum and were kept in regular
alternate 12 h cycles of light and dark. Nude mice were
housed in isolation cabinets. All animal experiments were
performed in accordance with a UK Home Office project
licence. MAC transplantable murine adenocarcinomas of the
colon were transplanted subcutaneously (s.c) into female
NMRI mice in the case of the MAC29 model and male mice
in the MAC1SA system; human HT29 colorectal tumour
fragments were implanted s.c. into nude mice. The
experiments were conducted and treatment initiated follow-
ing established procedures for the particular tumour model as
reported before (Double et al., 1975; Hill et al., 1992; Collard
et al., 1995).
Drug treatment and assessment ofactivity Drugs were given
as i.p. bolus injections in therapeutic doses as assessed before
treatment. 5-FU was administered at 125 mg kg-' body
weight (70% LD10), C1310 and C1311 were given in doses of
25, 50 and 100 mg kg-' in the MAC1SA tumour system and
100 mg kg-1 in the MAC29 model respectively. HT29-
bearing mice were treated with 50 and 100 mg kg -' C1311.
Control mice received vehicle (normal saline solution) only. A
minimum group size of six animals was used. Treatment
commenced when tumours could be measured reliably by
calipers, i.e. had reached minimum dimensions of 4 x 5 mm.
Tumour growth was followed by serial caliper measurements
and body weight was recorded simultaneously. Anti-tumour
activity was assessed by tumour volume (Geran et al., 1972)
and growth delay was determined by comparison of the
median time taken to reach a relative tumour volume (RTV)
of 2 in treated (T) vs control (C) MAC29 and HT29 tumours
or RTV of 5 for MAC1SA tumours. The significance of these
results was tested applying Mann-Whitney non-parametric
statistics. Results were also expressed as percentage growth
delay in which a positive number indicated that the treated
tumour reached the RTV of 2 and 5, respectively, more
slowly than the control tumour, and as optimum percentage
T/C (day), a parameter used by the NCI in vivo screening
programme. Percentage treated/control was calculated by
dividing the median treated tumour weight by the median
control tumour weight on each observation day and
multiplying by 100. The optimum %T/C and the day on
which it occurred was recorded (Dykes et al., 1992;
Hernandez et al., 1995). An optimum %T/C of greater than
40 was considered inactive.
Fluorescence microscopy
Intracellular distribution of C1310 and C1311 was studied
by fluorescence microscopy using a Vickers M17 micro-
scope (Optivision, Ossett, UK). Since the compounds have
a fluorochromic structure, they are highly fluorescent with
an excitation maximum at about 340 nm (emission
520 nm). Approximately 5 x 106 HT29 colon carcinoma
cells were treated with C1310 and C1311 for 10, 30 and
60 min at IC50 and TGI concentrations. Cells were then
trypsinised, transferred into 15 ml tubes, washed twice with
phosphate-buffered saline (PBS) and kept at 4°C. Localisa-
tion of fluorescence was examined for each sample/time
point and documented in a series of fluorescence
photomicrographs.
DNA binding analysis
DNA-binding properties of the imidazoacridinone derivative,
C1311, in comparison with the known DNA binder,
doxorubicin, were tested by spectrophotometric titration,
thermal denaturation and Scatchard plot studies following
procedures described elsewhere (Double and Brown, 1975;
Plumbridge et al., 1978; Islam et al., 1985). CT (Calf thymus)
DNA [Sigma type I; 2.5 x 10-3 M (P), concentration
determined from the equation E (P)260=6600] and drug
solutions (5 x 10-I M) were prepared in isotonic Tris-HCl
buffer, pH 7.4, and measurements performed using a Perkin-
Elmer Lambda-5 UV/VIS spectrophotometer with a fitted
Peltier temperature programmer, PTP-6 (Perkin-Elmer,
Beaconsfield, UK). Thermal denaturation of CT-DNA was
measured at a DNA-drug ratio of 10:1 and the final DNA-
drug ratio for spectrophotometric titration experiments was
at least 20:1. The compounds tested obeyed Lambert-Beer's
law over the concentration range used. DNA-binding
parameters, K and n, were estimated by linear regression
analysis of Scatchard plot data transformation (Double and
Brown, 1975; Plumbridge et al., 1978).
Figure 1
C1311.DNA synthesis
Approximately 106 log-phase growing HT29 cells cultured in
6-well plates were treated at approximately IC50 (0.5 ,uM) and
TGI (2 gM) concentrations of C1311. DNA synthesis was
studied by following the incorporation of a 2 h or 1 h pulse,
respectively, of [3H]thymidine (specific activity 70-86 Ci
mmol-'; Amersham International, Little Chalfont, UK) into
HT29 cells after exposure to drug for 1, 4 and 8 h. Controls
were untreated cells pulsed for 2 h with [3H]thymidine.
Following three washes with ice-cold PBS, cells were lysed
in 1% Triton-X-100/PBS solution for 15 min at 4°C and the
lysate assayed for protein content using the BCA Protein
Assay (Pierce, Rockford, IL, USA). An aliquot of 50 ,g of
protein was counted in 10 ml of EcoLite Liquid Scintillation
Cocktail (ICN Pharmaceuticals, Thame, UK) using a
Beckman LS 6000SC Liquid Scintillation Analyser (Beck-
man Instruments, High Wycombe, UK) and results were
expressed as counts per minute per mg of protein.
Results
Biological properties in vitro
Growth inhibition The MTT colorimetric assay for viable
cell mass was used to determine the effect of 'continuous'
Imidazoacridinones in colon cancer
AM Burger et al ;
1371
exposure (6 days) on cell growth. C1310 and C1311 inhibited
the growth of six human (colon and leukaemia) tumour cell
lines, three murine (colon and leukaemia) tumour cell lines
and one human fibroblast (breast) cell line examined.
Differential sensitivity was observed between drug concentra-
tions necessary for achieving 50% growth inhibition (IC50)
and drug concentration needed to induce total growth
inhibition (TGI) and between slow-growing cell lines, such
as the human fibroblast line BTS-30 (IC50 ranging between
7.7 and 16 gIM), compared with fast-growing cells like the
human K-562 chronic myelogenous leukaemia (IC50s are 47-
250 nM) (Table I). While IC50 concentrations for C1310 and
C1311 in the human colon cancer cell lines ranged between
10 nM and 1.85 ,UM, TGI concentrations were often 10 x IC50
and higher, needing up to 50 gUM. The most sensitive human
colon carcinoma cell line to both compounds was SW-620
with an IC50 for C1311 of 10 nM. C1311 was more potent in
six out of ten cell lines with regard to IC50 values, whereas
C1310 was more active in achieving total growth inhibition
(Table I).
Duration of drug exposure To assess the influence of length
of drug exposure, HT29 cells or MAC15A cells, respectively,
were exposed for varying time periods to concentrations
(Table I) that just inhibited cell growth by 50% and/or
completely (TGI) after 6 days of continuous exposure to the
Table I Tumour cell growth inhibition by C1310 and C1311
IC50 (MM)a TGI (PM)a
Cell line C1310+s.e. C1311+s.e. C1310 C1311
Murine
Colon
MAC1SA 0.013+0.005 0.036+0.007 15.0 18.5
MAC26 5.5+ 1.3 14.2+3.8 19.0 34.0
Leukaemia
WEHI-3B 0.014+0.009 0.005+0.0004 0.1 0.1
Human
Colon
HT29 0.50+0.1 0.36+0.08 18.0 1.25
HCT-116 0.30+0.06 0.33+0.02 4.7 9.0
KM12 1.50+0.25 0.36+0.03 5.0 2.1
DLD-1 1.05+0.05 1.85+0.05 8.75 50.0
SW-620 0.22+0.07 0.01 +0.002 0.9 0.03
Leukaemia
K-562 0.25+0.02 0.047+0.007 0.8 2.35
Fibroblast
BTS-30 7.7+2.3 16.0+9.7 > 50 > 50
aData based on MTT assay after 6 days of continuous exposure to drug. IC50 represents drug
concentration to achieve 50% growth inhibition; TGI represents drug concentration required for total
growth inhibition.
Table II Activity of C1310/C1311 in in vitro colon carcinoma models compared with 5-FU as
standard agent
Drug/dose Growth delay Optimum % TIC
Tumour (n/d)a (mg kg-') (%) (day)
Murine
MAC15A (6/0) C1310/25 -35.2 46.7 (4)
(6/0) C1310/50 7.4 58.2 (4)
(6/0) C1310/100 46.3 37.8 (4)
MAC15A (6/0) C1311/25 -3.7 57.3 (4)
(6/0) C1311/50 55.5 33.5 (4)
(6/0) C1311/100 251.8 6.5 (4)
MAC15A (6/0) 5-FU/125 144.0 5.6 (4)
MAC29 (10/0) C1310/100 -32.8 55.2 (10)
MAC29 (10/0) C1311/100 117.8 32.1 (10)
MAC29 (10/0) 5-FU/125 58.1 40.8 (10)
Human xenograft
HT299 (12/1) C1311/50 68.6 37.8 (18)
(12/1) C1311/100 211.4 21.5 (15)
aNumber of tumours/animal death.Imidazoacridinones in colon cancer
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drug. Drug was then removed at various intervals and cells
were incubated in drug-free medium for a total of 6 days.
Persistent growth inhibition was already achieved after 1 h
exposure at lethal concentrations of both drugs, when
assayed by viable cell mass 6 days after drug removal. At
IC50 concentrations, approximately 24 h was needed to
inhibit growth by 50%, with C1310 being slightly more
effective at 4 h and 8 h than C1311.
In vivo studies
In vivo activity of both compounds was assessed in
transplantable murine and human colorectal carcinomas. 5-
FU, the most frequently used standard agent for tumours of
the colon (Rubio-Diaz et al., 1990), was used as a positive
a
0 E
0
E
.)
Cu
a)
control (Table II). In this study, drugs were evaluated in
three different s.c. tumour models, the fast-growing MACI5A
adenocarcinoma, the well-differentiated glandular adenocar-
cinoma MAC29 and the human xenograft HT29. All three
tumours responded to a single dose of 100 mg kg-' body
weight C1311 after i.p. administration with statistically
significant growth delays (P<0.01, Mann-Whitney U-test)
ranging between 118% and 252% (Table II). As shown in
Figure 2a, 100 mg kg-' C1311 produced a similar growth
delay in MAC29 tumours to 5-FU at a dose of 125 mg kg-'.
The human xenograft HT29 also responded well to C1311
treatment (Figure 2b), but the drug was less well tolerated in
nude mice causing an isolated animal death (Table II). No
acute toxicity was observed in NMRI mice at the doses used
(25, 50 and 100 mg kg-'). Although showing similar in vitro
activity to C1311, C1310 was not very active in both murine
colorectal cancer models tested. On the contrary, low doses
of 25 mg even appeared slightly to increase tumour growth
(Table II). Data depicted in Figure 2a and b and Table II
have been confirmed in another independent experiment in
each case.
Uptake and distribution of C1310/C1311 into cells
The uptake of C1310/C1311 into living cells was studied in
vitro by fluorescence microscopy and is illustrated in Figure
3. C1311 and C1310 drug uptake and internalisation was
followed in HT29 colon carcinoma cells over several time
points at concentrations inducing 50% and 100% growth
inhibition (Table I). We found that C1310 and C1311
fluorescence was rapidly detectable in the nuclear regions of
HT29 cells at both concentrations tested. Fluorescence was
Time (days)
b
E
0
E
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Time (days)
Figure 2 (a) In vivo anti-cancer activity. C1310 (0) and C1311
(V) activity against murine transplantable adenocarcinoma of the
colon MAC29 compared with 5-FU (V) and vehicle control (El).
Doses were administered as i.p. bolus with 100mgkg-' for C1310
and C1311 and 125mgkg-1 for 5-FU. Data represent median
relative tumour volume (n = 10 animals per treatment). lb) HT29-
bearing athymic nude mice were treated with 50mgkg - (V) and
100mgkg- (V) C1311 or normal saline as vehicle control (0).
Results are shown as median relative tumour volume (n = 12).
Figure 3 Fluorescence microscopy. HT29 cells treated with
0.5,UM C1311 for 10min. Open arrow indicates compound
fluorescence localised in the cell nuclei; white arrow indicates
punctate concentration in cytoplasmic organelles. Original
magnification x 800.Imidazoacridinones in colon cancer
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observed as early as 10 min after treatment at IC5s (e.g.
0.5 gM in HT29) and intensified with increasing concentra-
tion and exposure periods. Interestingly, as depicted in Figure
3 for C1311 in HT29 cells, the compounds were not only seen
to accumulate in nuclei but also in discrete cytoplasmic
structures in nearly all the cells treated.
DNA binding studies
Spectrophotometric titration studies revealed a clear isos-
bestic point for C1311 at 456 nm ilrnax 425 nm), which is
indicative of the presence of only two species of ligand, a
single distinct bound form of drug in addition to free drug
(Double and Brown, 1975). Such a linear binding equilibrium
suggests the existence of a single class of internal binding sites
for the interaction of the compound with CT-DNA (Blake
and Peacock, 1968). Doxorubicin, used as standard agent
under the same conditions, showed an isosbestic point at
545 nm (A.max 477 nm).
The estimated association constant for formation of bound
ligand -DNA complex, K, derived from Scatchard plot
analysis gave a K value of 3.1 x 106 M-l with n=0.35 in
the case of C1311. For doxorubicin, K was 2.36x 106 M-
with n=0.31. The n value represents the number of sites
available for drug binding per DNA phosphate (Blake and
Peacock, 1968). An n value of about 0.3 would imply that a
drug molecule fits into the CT-DNA approximately every 3
basepairs. Higher values obtained for C1311 in comparison
with doxorubicin could reflect a higher binding affinity and
binding frequency of C1311 to CT-DNA and might be
explained by a better fit of the diethylamino side-chain of
C1311 (Figure 1) to the DNA helix compared with the longer
amino sugar residue of doxorubicin.
The DNA-binding properties of C1311 were further
reflected in the stabilisation of CT-DNA (melting point
73.5°C) to thermal denaturation. A Tm value (temperature at
which the half-maximum of absorbance was observed) for
C1311 was determined at 86°C, resulting in a ATm of 12.5°C.
Tm for doxorubicin was found to be 88.5°C, giving a ATTm of
15°C. When a molecule binds into the DNA helix, the
macromolecule is stabilised and more energy is required to
separate the strands, thus increased DNA melting points (Tm
values) can be considered indicative of the previously
described drug-DNA interactions (Neidle et al., 1987).
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Figure 4 Time course of C1311 effect on DNA synthesis. HT29
cultures were exposed at IC50 concentrations (= Z) and TGI
concentration ( ) for 1, 4 and 8h and pulsed parallel to drug
addition or for the final 2h with [3H]thymidine. Control cells
( _) received a 2h pulse only. Results are depicted as counts
per minute per mg of cellular protein and represent the
mean+ s.e. of three independent determinations.
DNA synthesis
In an effort to delineate the antiproliferative activity of
C1310/C1311 further, we studied the effects on DNA
synthesis following [3H]thymidine incorporation over various
time points. The data reflect the results of the exposure
duration studies described above. As depicted for C1311
(Figure 4), after only 1 h of exposure of HT29 cells to TGI
(2.0 gM) concentration, thymidine incorporation was signifi-
cantly reduced by about 70% compared with untreated cells.
Eight hours of drug exposure caused approximately 90%
inhibition of thymidine incorporation, whereas IC50 (0.5 jM)
doses were not very effective before 8-24 h.
Discussion
The experiments presented in this article demonstrate that the
imidazoacridinones, C1310 and C1311, inhibit the growth of
a variety of murine and human colon carcinoma cell lines
with IC50 ranging from 10 nM to about 2 gM in the human
cell lines examined by 6 day in vitro assay. The cell lines
differed in their susceptibility to the two drugs, especially
with regard to total growth inhibition, e.g. C1311 required
30 nm in SW-620 cells, but 50 jgM in the DLD-1 cell line. The
slow-growing fibroblast cell line BTS-30 was the least
sensitive, and total growth inhibition was not observed at
the maximum concentrations employed. In vivo experiments
performed as single i.p. dose administration in three different
colorectal carcinoma models showed statistically significant
growth delay by C1311. At the highest dose tested, C1311
appeared at least as active against the MAC tumours as 5-
FU, whereas C1310 did not induce significant growth delay.
Growth inhibition in vitro appears to be related to DNA
damage as intimated by rapid localisation of compound
fluorescence in the nuclei of living cells, and early inhibition
(1 h) of thymidine incorporation in HT29 cells. The
physicochemical CT-DNA/C1311 interactions determined in
this study are consistent with these effects in living cells and are
indicative of similar binding properties for C1311 to doxor-
ubicin. The data suggest that DNA binding may be important
for the compound's antiproliferative effect. The DNA-binding
parameters found for doxorubicin in all the experiments
described here are similar to previously reported values
(Double and Brown, 1975; Plumbridge and Brown, 1979).
The difference between concentrations needed to achieve
total growth inhibition among the colorectal tumour cell lines
examined (Table I) is of interest and might be explained
either by variance in growth rates or in the DNA repair
enzyme status of these cells. Determination of both IC50 and
TGI is a useful exercise as it might facilitate selection of the
most appropriate human cell line for in vivo study. Steep
dose - response curves with small differences between IC50
and TGI values, e.g. HT29 (Table I), might predict for in vivo
activity.
Although binding into DNA is likely to be involved
initially in the effects C1310 and C1311 impose on cells,
additional mechanisms might well be operative and con-
tribute to the observed differences in growth inhibition and
cell death induced by these imidazoacridinones. Indeed, a
cascade of secondary drug effects, such as DNA cross-linking
after metabolic activation or topoisomerase inhibition and
DNA fragmentation following the initial distortion of DNA
integrity by intercalation, have previously been discussed for
closely related classes of compounds (Konopa, 1990; Denny,
1989; Skladanowski and Konopa, 1993). Very recent studies
have demonstrated that C1310 and C1311 inhibit the
catalytic activity of purified topoisomerase II and stimulate
the formation of cleavable complexes in vitro (Skladanowski
et al., 1996).
Although no major differences between C1310 and C1311
were observed in vitro, C1310 is strikingly less active in vivo
than C1311 (Table II). The poor response of the colorectal in
vivo tumour models to C1310, which is distinguished by just
1373Imidazoacridinones in colon cancer
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one methyl group from C1311 (Figure 1), may be caused by
differences in pharmacokinetics. In this context, the in vitro
data demonstrate that duration of exposure is important for
activity and suggest that TGI levels need to be present for at
least 1 h to achieve significant effects. The pharmacokinetic
behaviour of the compounds is currently under detailed
investigation and will be reported elsewhere. Future work will
also include a study of the influence of route of
administration and dosage scheduling on the anti-tumour
activity of C1311. However, the data presented in this study
indicate that C1311, in particular, has good activity against
the model systems examined. In addition to the in vivo
activity against colon carcinomas, the lack of free oxygen
radical production suggests that this compound has potential
for clinical development.
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